An observational study in Schizophrenia, sponsored by Janssen-Cilag, S.A.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-03-19.
Sponsored by Janssen-Cilag, S.A. (part of Johnson & Johnson) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 206 studies in Schizophrenia by Johnson & Johnson — 2 open to participants now, 2 under way, 1 of them phase 3. Schizophrenia · Johnson & Johnson.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 5th largest by enrollment of the 30 observational ones that give a count, is one of 16 that started in 2006, is one of 30 observational ones, and was the 54th registered.
3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →2 of the 206 studies in Schizophrenia by Johnson & Johnson are open now, in 3 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States
Ages 18–60
Intra-Cellular Therapies, Inc. · Sites in United States, Colombia, Serbia
Ages 5–17
By country, each count listing its studies:
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
206 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 43 · Phase 2 12 · Phase 3 74 · Phase 4 47
First in 1996; this study’s year is marked. 16 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,339 is above the median of 178 across 508 observational studies indexed under Schizophrenia.
Median enrollment 165 across the 176 interventional studies, 541 across the 30 observational. Of the 203 that completed or were terminated, 57 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen-Cilag, S.A., one of the names counted as Johnson & Johnson. Under that name alone:
Janssen-Cilag, S.A. is the lead sponsor of 21 studies on the registry; 1 is open to participants now.
1 of the studies in Schizophrenia by Johnson & Johnson that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07615426Janssen Research & Development, LLCA Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia | 2027-06-21 |
Add it to your calendar (.ics) → With an account.
Among the 206 studies in Schizophrenia by Johnson & Johnson, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to establish and validate a scale/model that can be used to evaluate the duration of time and factors between short term hospital treatment and subsequent relapse periods in patients with schizoaffective/schizophreniform disorders.
This is an epidemiological (study of the distribution and determinants of health-related states or events in defined population), multicenter (study conducted at multiple sites), observational (study in which patients are observed), cross-sectional (observation of all patients at one specific point in time), prospective (in which the patients are first identified and then followed forward as time passes) study. The sources of information in the study are units medical short stay psychiatric hospitalization or the acute care of the whole country, and clinical data of the patient at discharge. No intervention will be provided in this study. The general data (age range, gender, highest level of educational attainment, level of family support, substance abuse, events stressors, type of schizophrenia according to DSM-IV criteria [Diagnostic and Statistical Manual fourth], etc) of approximately 2000 schizophrenia and schizoaffective disorder / schizophreniform patients will be collected in this study. No special tests will be done during the study. The study will collect patients' data in electronic data collection workbook and model validation will be used at 6 and 12 months to confirm no relapse / hospitalization. The study observation period corresponds to the 3 years preceding the current relapse and current income (current hospitalization period) and 12 months after admission.
Patients with schizophrenia, schizoaffective / schizophreniform more than 2 years of evolution and who are admitted to inpatient psychiatric units for short stay acute care setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: No intervention
This is an observational study. The data will be collected of patients suffering from schizophrenia and schizoaffective disorder / schizophreniform.
Time to short-term relapse
Time to early relapse of patients discharged from a short-stay psychiatric hospitalisation unit.
Time frame: Up to 12 months
Number of readmission of patients
Readmission in short-stay psychiatric hospital units when the schizophrenia or schizoaffective or schizophreniform disorder relapse.
Time frame: Up to 12 months
Clinical Global Impression - Severity (CGI-S) Score
The CGI-S rating scale is used to rate the severity of a patient's psychotic condition on a 7-point scale. It is rated as follows: 1=Normal, not at all ill, 2=Borderline mentally ill, 3=Mildly ill, 4=Moderately ill, 5=Markedly ill, 6=Severely ill, and 7=Among the most extremely ill. Higher scores indicate worsening.
Time frame: Up to 3 years
Duration of disease
Time frame: Within 3 years before the study start
Drug abuse
Time frame: Within 3 years before the study start
Psychiatric diagnosis
Patients diagnosed with Schizophrenia or Schizoaffective/schizophreniform disorder.
Time frame: Within 3 years before the study start
Previous stress or event
Time frame: Within 3 years before the study start
Hospitalizations in the previous 3 years
Time frame: Within 3 years before the study start
Adherence to the psychiatric treatment
Time frame: Within 3 years before the study start
Previous pharmacological treatment
Time frame: Within 3 years before the study start
No study locations are listed for this record.
The record gives a start of Aug 2006, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.